Optimization of anti-CD19 CAR T cell production for treatment of patients with chronic lymphocytic leukemia

Christina Amatya(National Institutes of Health), James N. Kochenderfer(National Institutes of Health)

Molecular Therapy — Methods & Clinical Development

February 13, 2024

10.1016/j.omtm.2024.101212

Cited by 5

Related Papers

Toxicities of chimeric antigen receptor T cells: recognition and management

|Blood|2016|1.4k

Long-term outcomes following CAR T cell therapy: what we know so far

|Nature Reviews Clinical Oncology|2023|1.2k

Adoptive transfer of syngeneic T cells transduced with a chimeric antigen receptor that recognizes murine CD19 can eradicate lymphoma and normal B cells

|Blood|2010|387

Anti-BCMA chimeric antigen receptors with fully human heavy-chain-only antigen recognition domains

|Nature Communications|2020|123